Measured-Effect VUS Reports for Hereditary Cancer Panels
A report for cancer labs that explains the actual effect of genetic variants that were previously labeled as uncertain.
A report add-on for hereditary cancer testing labs that pulls experimentally measured variant-effect scores (MaveDB MAVE data) for each variant of uncertain significance on a panel and turns them into curator-ready functional-evidence summaries.
Concept
A report add-on for hereditary cancer genetic testing labs. For every variant of uncertain significance (VUS) returned on a patient's panel, the service checks MaveDB for multiplexed assays of variant effect (MAVEs — saturation-mutagenesis experiments) covering the affected functional element, pulls the measured effect score at that exact position, renders it in the positional-heatmap format the UCSC Genome Browser now uses for MaveDB data, and emits a curator-ready evidence summary: measured score, assay type, and the weight that measured functional evidence can carry under ACMG/AMP classification criteria. Variants with no measured coverage are flagged as such rather than filled in with predictions — the single wedge is experimentally measured evidence, so curators always know what is grounded and what is not.
Why now
The 2026 UCSC update integrates MaveDB MAVE data into the browser with a positional heatmap display for point mutations in functional elements — a signal that measured, per-position variant-effect data is now standardized and mature enough to be a first-class browsable resource rather than a niche supplement scattered across individual publications. The same release sharpens functional interpretation of coding variants elsewhere (the ClinVar track now marks protein-truncating splice-acceptor, splice-donor, frameshift, and nonsense variants with colored diamonds on both hg19 and hg38), confirming that functional-consequence evidence is an active priority for the community. VUS burden remains the top complaint for hereditary cancer panels; the browser integration shows the measured data is now accessible enough to build a classification-evidence product on top of it.
Written by GLM · 10 Oct 2026
AI assessment
A highly focused, high-utility tool that converts standardized experimental data into clinical evidence, solving a specific pain point for genetic curators.
- Evidence strength 5/5
- The idea directly leverages the 2026 UCSC update's integration of MaveDB data, moving from fragmented papers to a standardized, browsable resource.
- Market pull 4/5
- VUS resolution is a critical bottleneck for major labs like Myriad and Invitae, and the ACMG guidelines explicitly value functional evidence.
- Novelty & moat 4/5
- Unlike the listed ideas that rely on predictions or general audits, this focuses exclusively on experimentally measured data, filling a gap for 'ground truth' evidence.
- Feasibility 5/5
- The MVP is a data-retrieval and formatting layer on top of existing MaveDB/UCSC APIs, requiring no new wet-lab experiments.
- Wedge clarity 5/5
- The wedge is extremely sharp: a specific report add-on for hereditary cancer panels focusing only on measured effects.
- Simplicity / focus 5/5
- It avoids 'platform' creep by doing one thing: turning MAVE scores into curator-ready summaries.
Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Ambry Geneticscompany
Its hereditary cancer panels return thousands of VUS results; measured MAVE scores are exactly the kind of functional evidence its curation team needs to reclassify them.
- Myriad Geneticscompany
The MyRisk hereditary cancer panel carries a large VUS burden; a standardized measured-evidence report directly supports its VUS-reduction strategy.
- Invitaecompany
Population-scale hereditary cancer testing volume makes VUS follow-up the dominant cost; measured-effect summaries prioritize which variants are worth expert review.
- Clinical Genome Resource (ClinGen)organization
Its variant curation expert panels standardize evidence classification; a per-variant measured MAVE summary with assay metadata feeds directly into their functional-evidence specifications.
Research it builds on
- The UCSC Genome Browser database: 2026 updateJonathan D. Casper, Matthew L Speir, Brian J. Raney et al. · 2025 · 141 citationsAll ideas from this paper →